New drug combo tested for rare blood cancer
NCT ID NCT05371964
Summary
This early-stage study is testing a new drug called imetelstat when given alongside an existing drug, ruxolitinib, for people with myelofibrosis, a serious bone marrow cancer. The main goals are to find a safe dose and see if the combination helps reduce symptoms like fatigue and pain, and shrinks enlarged spleens. It will involve about 36 participants who are already taking or are candidates for ruxolitinib treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
City of Hope
RECRUITINGIrvine, California, 92618, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center and Research Institute, Inc.
RECRUITINGTampa, Florida, 33612, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Texas Oncology
WITHDRAWNDenison, Texas, 75020, United States
-
Texas Oncology
WITHDRAWNTyler, Texas, 75702, United States
-
University of Miami
RECRUITINGCoral Gables, Florida, 33146, United States
Conditions
Explore the condition pages connected to this study.